The investing icon helped Buffett build Berkshire Hathaway.
Both of these stocks have been big winners this year. But one could be better positioned to extend that winning streak over the next decade.
One area to focus on is companies that generally offer steady earnings growth over time. CRISPR Therapeutics (NASDAQ: CRSP) just reached a huge milestone, and another may be just ahead. The company recently won the world's first authorization for a CRISPR-based gene-editing treatment when the U.K. gave the nod to exa-cel (to be commercialized as Casgevy).